Key result
Sacubitril/valsartan reduces renal events and slows eGFR decline versus valsartan in HFpEF.
Why the study?
Does sacubitril/valsartan reduce the risk of renal events and slow the decline in eGFR in patients with heart failure with preserved ejection fraction compared to valsartan?
Does sacubitril/valsartan reduce the risk of renal events and slow the decline in eGFR in patients with heart failure with preserved ejection fraction compared to valsartan?
Sacubitril/valsartan provides renal protective benefits by reducing renal events and slowing eGFR decline in patients with HFpEF compared to valsartan alone.
Answers are grounded in this paper and cite their sources.
Supports sacubitril/valsartan for renal protection in HFpEF; extends outcome data to kidney endpoints in this population.
In patients with heart failure with preserved ejection fraction, sacubitril/valsartan reduced the risk of renal events, and slowed decline in eGFR, in comparison with valsartan. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01920711.
No takes yet. Share an insight, caveat, or question.
Causland et al. (2020) studied this question. Sacubitril/valsartan reduced the risk of renal events and slowed decline in eGFR compared with valsartan in patients with heart failure with preserved ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: